Vet Microbiol 2009, 135:320–326.PubMedCrossRef 35. Bannoehr J, Zakour NL, Reglinski M, Inglis N: Genomic and Selleckchem PCI-34051 surface proteomic analysis of the canine pathogen Staphylococcus pseudintermedius reveals protein that mediate adherence to the extracellular matrix. Infect Immun 2011, 79:3074–3086.PubMedCentralPubMedCrossRef 36. Mikuniya T, Kato Y, Ida T: Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect

Chemother 2007, 13:285–290.PubMedCrossRef 37. Parra-Ruiz J, Vidaillac C, Rybak MJ: Macrolides and staphylococcal biofilms. Rev Esp Quimioter 2012, 25:10–16.PubMed 38. Parsek MR, Greenberg EP: Sociomicrobiology: the connections between quorum sensing and biofilms. Trends Microbiol 2005, 13:27–33.PubMedCrossRef 39. Stepanovic S, Vukovic D, Hola V, Di Bonaventura G, Djukic S, Sapanisertib manufacturer Cirkovic

I, Ruzicka F: Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. APMIS 2007, 115:891–899.PubMedCrossRef 40. Bannoehr J, Ben Zakour NL, Waller AS, Guardabassi L, Thoday KL, Broek VAH, Fitzgerald JR: Population genetic structure of the Staphylococcus intermedius group: Insights into agr diversification and the emergence of methicillin-resistant strains. J Bacteriol 2007, 189:8685–8692.PubMedCentralPubMedCrossRef 41. Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estevez R, Canton E, Gobernado M:

In vitro activity of linezolid in selleck chemical combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter 2006, 19:252–257.PubMed 42. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ: Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 2010, 54:4329–4334.PubMedCentralPubMedCrossRef Enzalutamide datasheet 43. Rodríguez-Martínez JM, Ballesta S, Pascual A: Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. Int J Antimicrob Agents 2007, 30:366–368.PubMedCrossRef 44. Takahashi K, Kanno H: Synergistic activities of combination of beta lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa . Antimicrob Agents Chemother 1984, 26:789–791.PubMedCentralPubMedCrossRef 45. Peng HL, Novick RP, Kreiswirth B, Kornblum J, Schlievert P: Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus . J Bacteriol 1988, 170:4365–4372.PubMedCentralPubMed 46. Yamada S, Hyo Y, Ohmori S, Ohuchi M: Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa . Chemotherapy 2007, 53:202–209.